858 related articles for article (PubMed ID: 21390126)
1. Inactivating mutations of acetyltransferase genes in B-cell lymphoma.
Pasqualucci L; Dominguez-Sola D; Chiarenza A; Fabbri G; Grunn A; Trifonov V; Kasper LH; Lerach S; Tang H; Ma J; Rossi D; Chadburn A; Murty VV; Mullighan CG; Gaidano G; Rabadan R; Brindle PK; Dalla-Favera R
Nature; 2011 Mar; 471(7337):189-95. PubMed ID: 21390126
[TBL] [Abstract][Full Text] [Related]
2. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
3. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
5. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Haery L; Mussakhan S; Waxman DJ; Gilmore TD
Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
[TBL] [Abstract][Full Text] [Related]
6. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.
Nie M; Du L; Ren W; Joung J; Ye X; Shi X; Ciftci S; Liu D; Wu K; Zhang F; Pan-Hammarström Q
Cell Death Dis; 2021 Apr; 12(5):419. PubMed ID: 33911074
[TBL] [Abstract][Full Text] [Related]
8.
García-Ramírez I; Tadros S; González-Herrero I; Martín-Lorenzo A; Rodríguez-Hernández G; Moore D; Ruiz-Roca L; Blanco O; Alonso-López D; Rivas JL; Hartert K; Duval R; Klinkebiel D; Bast M; Vose J; Lunning M; Fu K; Greiner T; Rodrigues-Lima F; Jiménez R; Criado FJG; Cenador MBG; Brindle P; Vicente-Dueñas C; Alizadeh A; Sánchez-García I; Green MR
Blood; 2017 May; 129(19):2645-2656. PubMed ID: 28288979
[TBL] [Abstract][Full Text] [Related]
9. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
11. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
12. Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma.
Bakhshi TJ; Way T; Muncy B; Georgel PT
Biochem Cell Biol; 2023 Apr; 101(2):172-191. PubMed ID: 36599133
[TBL] [Abstract][Full Text] [Related]
13. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
14. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Morin RD; Mendez-Lago M; Mungall AJ; Goya R; Mungall KL; Corbett RD; Johnson NA; Severson TM; Chiu R; Field M; Jackman S; Krzywinski M; Scott DW; Trinh DL; Tamura-Wells J; Li S; Firme MR; Rogic S; Griffith M; Chan S; Yakovenko O; Meyer IM; Zhao EY; Smailus D; Moksa M; Chittaranjan S; Rimsza L; Brooks-Wilson A; Spinelli JJ; Ben-Neriah S; Meissner B; Woolcock B; Boyle M; McDonald H; Tam A; Zhao Y; Delaney A; Zeng T; Tse K; Butterfield Y; Birol I; Holt R; Schein J; Horsman DE; Moore R; Jones SJ; Connors JM; Hirst M; Gascoyne RD; Marra MA
Nature; 2011 Jul; 476(7360):298-303. PubMed ID: 21796119
[TBL] [Abstract][Full Text] [Related]
15. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
16. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
17. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells.
Vlasevska S; Garcia-Ibanez L; Duval R; Holmes AB; Jahan R; Cai B; Kim A; Mo T; Basso K; Soni RK; Bhagat G; Dalla-Favera R; Pasqualucci L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2218330120. PubMed ID: 36893259
[TBL] [Abstract][Full Text] [Related]
18. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
19. A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.
Garbati MR; Thompson RC; Haery L; Gilmore TD
Cancer Lett; 2011 Mar; 302(1):76-83. PubMed ID: 21232847
[TBL] [Abstract][Full Text] [Related]
20. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]